Newsroom
Inspections passed, capacity opened, partnerships signed — the record of a platform in motion.
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences…
Read the releaseCouvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life…
Read → Nov 14, 2024First operational building dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates.
Read → May 23, 2024Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board; Dr. Minzhang Chen, Co-CEO, WuXi AppTec; Mr. Heng Swee Keat, Deputy Prime Minister; Dr. Ge Li, Chairman and CEO,…
Read → Apr 9, 2024Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide…
Read → Mar 21, 2024Exciting moment! We’ve been honored with the 2024 CDMO Leadership Awards in all six core categories: Capabilities, Compatibility, Expertise, Quality, Reliability, and Service, again! Dr.…
Read → Jan 8, 2024Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand
Read → Jul 17, 2023Shanghai, China, July 17, 2023 — WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), today launched its first high potency (HP), fully automated…
Read → May 23, 2023SHANGHAI, CHINA, May 23, 2023 – WuXi STA, a subsidiary of WuXi AppTec, and Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a strategic partnership for the commercial supply of…
Read → Apr 5, 2023Expansion Enhances WuXi TIDES CRDMO Platform Capability and Capacity for Global Partners
Read → Mar 16, 2023We are pleased to invite you to the WuXi TIDES forum, titled “ Accelerating Oligonucleotide Therapeutics from Concepts to Patients “, which will be held on the pre-event day of the 10th…
Read → Feb 24, 2023WuXi STA, a global leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to share that it has been named a recipient of the 2023 CDMO Leadership Award…
Read → Jan 3, 2023SHANGHAI, CHINA, January 3, 2023 – WuXi STA, a subsidiary of WuXi AppTec, today announced that its first drug product Continuous Manufacturing (CM) line for oral solids is in operation at…
Read → Dec 13, 2022WuXi STA, a subsidiary of WuXi AppTec, received the latest scores from EcoVadis rating, a trusted provider of business sustainability ratings, for active pharmaceutical ingredients (API) R&D…
Read → Dec 1, 2022Personalized doses now can be filled into single – or multi – compartment capsules for GMP manufacturing
Read → Nov 30, 2022Shanghai, China, November 30, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced a new parenteral formulation manufacturing line has started operation at the drug product site in…
Read → Oct 12, 2022SHANGHAI, CHINA, October 12, 2022 – WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its three manufacturing sites in…
Read → Sep 30, 2022New service further accelerates drug candidates to clinical trials through CRDMO platform
Read → Sep 26, 2022New facility expands integrated drug product R&D and manufacturing services to global customers
Read → Sep 9, 2022Shanghai, China, September 9, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing…
Read → Aug 16, 2022MIDDLETOWN, Delaware, August 16, 2022 – WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new…
Read → Jul 19, 2022SINGAPORE, July 19, 2022 – WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to…
Read → Jul 15, 2022Company continues to enhance the flow chemistry platform for more sustainable production
Read → Jul 7, 2022Shanghai, China, July 7, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou…
Read → Jun 24, 2022Shanghai, China – June 24, 2022 – WuXi STA, a WuXi AppTec company, has opened another high-potency API (HPAPI) plant at its Changzhou site (Jiangsu, China). The new plant is added to meet…
Read → Mar 21, 2022We thank DCAT for the opportunity to share our capability and capacity expansion plan at the Member Company Announcement Forum during DCAT week last month. We hope our investment across API…
Read → Mar 3, 2022SHANGHAI, CHINA, March, 3, 2022 –WuXi STA – a subsidiary of WuXi AppTec – today announced that its drug product facility in Wuxi City, China has successfully passed its first pre-approval…
Read → Feb 21, 2022SHANGHAI, CHINA, WuXi STA – a subsidiary of WuXi AppTec– and Hua Medicine (SEHK stock code: 2552.HK) today announced signing a supply agreement for the commercial manufacturing of…
Read → Feb 8, 2022Shanghai, China, February 8, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities,…
Read → Jan 21, 2022Shanghai, China, January 21, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced its first parenteral formulation manufacturing line at the Wuxi city site is now in commission.…
Read → Jan 4, 2022SHANGHAI, CHINA, January 4, 2022 – WuXi STA – a subsidiary of WuXi AppTec, announced that its Waigaoqiao site in Shanghai, China, successfully passed the first drug product pre-approval…
Read → Dec 23, 2021WuXi STA was announced as the winner of Roche’s “2020 CDMO Award” for the best project-related performance of a CDMO in a given year.
Read → Dec 16, 2021SHANGHAI, CHINA, WuXi STA – a subsidiary of WuXi AppTec– and Xynomic Pharmaceuticals (Nanjing) Co., Ltd. (“Xynomic”) announced the signing of a strategic partnership agreement.
Read → Nov 22, 2021SHANGHAI, CHINA，WuXi STA – a subsidiary of WuXi AppTec– and Coherent Biopharma, announced the signing of a strategic partnership agreement.
Read → Nov 8, 2021NEW YORK, November 8, 2021 – Hoth Therapeutics, Inc., a patient focused biopharmaceutical company, announced today that it has entered into contracts with STA Pharmaceutical, a subsidiary of…
Read → Aug 3, 2021State-of-the-art facility significantly enhances WuXi STA’s drug product capacity in Europe while better enabling global customers
Read → Jul 21, 2021STA Pharmaceutical Co., Ltd., a WuXi AppTec Company (WuXi STA)–and BioNova Pharmaceuticals (Shanghai) Ltd. (“BioNova”) recently announced the signing of a collaboration agreement to jointly…
Read → Jul 16, 2021SHANGHAI, CHINA, July, 16, 2021 –STA Pharmaceutical Co., Ltd., a WuXi AppTec Company (WuXi STA)–and InnoCare Pharma Limited (HKEX: 09969), announced the signing of a strategic partnership…
Read → Jun 28, 2021WILMINGTON, Del. (June 28, 2021) — WuXi STA and Delaware Prosperity Partnership today announced that WuXi STA, a leading Contract Development and Manufacturing Organization (CDMO), will…
Read → Jun 3, 2021SHANGHAI, CHINA, June, 3, 2021 –STA Pharmaceutical Co., Ltd., (“WuXi STA”), a leading Contract Development and Manufacturing Organization – and Ascentage Pharma (6855.HK), announced the…
Read → May 20, 2021Wuxi city, China, May 20, 2021- STA Pharmaceutical, a WuXi AppTec company, today announces the opening of a new R&D center in Wuxi city site. With the new facility in operation, the Wuxi…
Read → May 14, 2021Shanghai, CHINA, May 14, 2021 –WuXi STA, a subsidiary of WuXi AppTec and WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms,…
Read → Apr 28, 2021On April 28, 2021, STA Pharmaceutical, a WuXi AppTec company, announced the construction of its Taixing site officially started. Located in Taixing Economic Development Zone, Jiangsu China,…
Read → Apr 12, 2021SHANGHAI, CHINA, April, 12, 2021 – STA Pharmaceutical, a WuXi AppTec company (WuXi STA), a leading contract development and manufacturing organization (CDMO) announces that three of its…
Read → Mar 15, 2021SHANGHAI, CHINA, March, 15, 2021 –STA Pharmaceutical Co., Ltd., (“WuXi STA”), a leading Contract Development and Manufacturing Organization – and AnHeart Therapeutics (Hangzhou) Co., Ltd.…
Read → Feb 25, 2021STA Pharmaceutical Co., Ltd., (“WuXi STA”), a leading Contract Development and Manufacturing Organization, announces that it has received 2021 CMO Leadership Awards in all six core…
Read → Feb 2, 2021NEW YORK & SHANGHAI — Bristol Myers Squibb (NYSE: BMY) and WuXi STA – a subsidiary of WuXi AppTec – today announced that WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing…
Read → Feb 1, 2021Shanghai China, February 1, 2021— STA Pharmaceutical Co., Ltd., (“WuXi STA”), a leading Contract Development and Manufacturing Organization, WuXi Biologics (“WuXi Bio”) (2269.HK), a global…
Read → Dec 25, 2020SHANGHAI, December 25, 2020: The National Medical Products Administration of China (NMPA) announced the approval of InnoCare’s Orelabrutinib, which got the support from the STA…
Read → Dec 2, 2020WuXi STA and WuXi Biologics to become Contract Development and Manufacturing Organization (CDMO) partners for Tubulis
Read → Jun 5, 2020Today, STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a leading biopharmaceutical company focusing on innovative,…
Read → Jan 2, 2020Shanghai, January 3, 2020: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide active pharmaceutical…
Read → Nov 20, 2019STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Impact Therapeutics, a biotech focused on innovative drug discovery and development in anti-cancer therapeutics,…
Read → Nov 18, 2019Yesterday, STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Impact Therapeutics, a biotech focused on innovative drug discovery and development in anti-cancer…
Read → Nov 12, 2019November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, announced…
Read → Nov 11, 2019November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, announced…
Read → Oct 28, 2019SHANGHAI, October 28, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility in Shanghai, China has…
Read → Jul 23, 2019SHANGHAI, 23 July, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) in Shanghai and active pharmaceutical…
Read → May 22, 2019STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the…
Read → Mar 27, 2019SHANGHAI, March 27, 2019 /PRNewswire/ — STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its new drug product manufacturing facility in Shanghai Pilot…
Read → Mar 22, 2019STA will Accelerate Process R&D and Manufacturing of Late Phase and Commercial Targets
Read → Mar 6, 2019STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Ark Biosciences, a global biotech company focusing on innovative drug discovery and development, especially in…
Read → Feb 19, 2019SHANGHAI and SAN DIEGO, Feb. 18, 2019 /PRNewswire/ — STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, and BioLingus, a Swiss biotech company, announce they have formed…
Read →How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA